Clinical Trial Update: Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Emavusertib (CA-4948) in combination with cisplatin, gemcitabine, and durvalumab in untreated advanced or metastatic biliary tract canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Emavusertib (CA-4948) (emavusertib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 1 | Status: RECRUITING